Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Botanix achieves record prescriptions for Sofdra despite temporary revenue decline

Botanix reported a record volume for Sofdra with 26,684 prescriptions delivered in the quarter and a monthly record in March, while net revenues temporarily fell from $9.1 million to $6.9 million due to the annual reset of deductibles in US health insurance plans. The GTN margin declined temporarily but is expected to normalize in the fourth quarter. The company strengthened its balance sheet with a $45 million capital raise, negotiated payment deferrals for API purchases, and signed a term-sheet agreement with Piramal that could reduce manufacturing costs by an estimated 25–40%. » Mere på de.investing.com
Botanix Pharmaceuticals achieves revenue growth and record prescription deliveries in Q3 2026

Botanix reported a gross revenue of AUD 120 million over the past 12 months and delivered 26,684 prescriptions in Q3. The gross-to-net margin improved from 16% to 19% by quarter-end, and the pro forma cash position is AUD 50.8 million. The stock fell 5% after the release. Management expects further margin improvement in Q4; projected EPS: -0.02 USD (2026) and -0.01 USD (2027), revenue forecasts: 27.71 million USD (2026) and 56.43 million USD (2027). » Mere på de.investing.com
Botanix: Sofdra revenue rises 28%, stock weighed down by higher costs

Botanix reported Q2 FY2026 net revenue of $9.1m, driven by a 24% increase in Sofdra prescriptions versus the prior quarter. The gross-to-net margin improved to 24% but remains below the 30–40% target range. Operating cash outflow rose to $17.2m after expanding the field sales force and higher operating expenses, worrying investors and sending the stock down 6%. Botanix has $31.5m in cash and $14.9m in undrawn credit lines; the challenge remains controlling costs and improving margins toward profitability. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 1996 har BOTANIX PHARMACEUTICALS allerede udloddet 88,44 € i udbytte. Den seneste udlodning fandt sted i oktober 1996.

Virksomhedstal

I det seneste kvartal havde BOTANIX PHARMACEUTICALS en omsætning på 10,91 mio. € og et nettoresultat på -22,15 mio. €

(EUR)	juni 2026	YoY
Omsætning	10,91 mio.	-
Bruttofortjeneste	-18,57 mio.	-
Nettoresultat	-22,15 mio.	-
EBITDA	-21,62 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	23,39 mio. €
Antal aktier	1,99 mia.
Højeste/laveste i 52 uger	0,11 € - 0,0111 €
Udbytte	Nej
Beta	0,86
P/E (PE Ratio)	-0,59
PEG (PEG Ratio)	-0,02
K/I (PB Ratio)	0,71
P/S (PS Ratio)	1,10

Virksomhedsprofil

Botanix Pharmaceuticals Limited, ein pharmazeutisches Unternehmen mit synthetischen Cannabinoiden im klinischen Stadium, beschäftigt sich mit der Erforschung und Entwicklung von dermatologischen und antimikrobiellen Produkten in Australien. Zu seiner Produktpipeline gehören BTX 1503, eine transdermale Gelformulierung zur Behandlung von schwerer Akne bei Erwachsenen und Jugendlichen, die klinische Studien der Phase II abgeschlossen hat; BTX 1801, das klinische Studien der Phase IIa zur Behandlung von Staphylococcus aureus und Methicillin-resistentem Staphylococcus aureus abgeschlossen hat; BTX 1702, das sich in klinischen Studien der Phase Ib zur Behandlung von papulopustulöser Rosazea befindet; und BTX 1204A zur Behandlung von atopischer Dermatitis. Das Unternehmen wurde 1984 gegründet und hat seinen Sitz in North Perth, Australien.